High Response Rate to Donor Lymphocyte Infusion after Allogeneic Stem Cell Transplantation for Indolent Non-Hodgkin Lymphoma

Biology of Blood and Marrow Transplantation

Volumn 14, Issue 1, 2008, Pages 50-58

  Bloor, Adrian J C ^a   Thomson, Kirsty ^a   Chowdhry, Noha ^a   Verfuerth, Stephanie ^a   Ings, Stuart J ^a   Chakraverty, Ronjon ^a   Linch, David C ^a   Goldstone, Anthony H ^a   Peggs, Karl S ^a   Mackinnon, Stephen ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Bone marrow transplantation; Donor lymphocyte; Lymphoma

Indexed keywords

ALEMTUZUMAB; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FLUDARABINE; MELPHALAN; METHOTREXATE; RITUXIMAB;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER GRADING; CHIMERA; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DONOR LYMPHOCYTE INFUSION; EVIDENCE BASED MEDICINE; FEMALE; GRAFT VERSUS LYMPHOMA EFFECT; HUMAN; INCIDENCE; MALE; MALIGNANT TRANSFORMATION; MYELOABLATIVE CONDITIONING; NONHODGKIN LYMPHOMA; REDUCED INTENSITY CONDITIONING; TREATMENT INDICATION; TREATMENT RESPONSE; WHOLE BODY RADIATION;

ADULT; DISEASE-FREE SURVIVAL; FEMALE; GRAFT VS HOST DISEASE; GRAFT VS TUMOR EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOCYTE TRANSFUSION; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RETROSPECTIVE STUDIES; SALVAGE THERAPY; TRANSPLANTATION CHIMERA; TRANSPLANTATION, HOMOLOGOUS;

EID: 37349000995     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2007.04.013     Document Type: Article

References (45)

1. Schimmer A.D., Jamal S., Messner H., et al. Allogeneic or autologous bone marrow transplantation (BMT) for non-Hodgkin's lymphoma (NHL): results of a provincial strategy. Ontario BMT Network, Canada. Bone Marrow Transplant 26 (2000) 859-864
2. Peniket A.J., Ruiz de Elvira M.C., Taghipour G., et al. An EBMT registry-matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation. Bone Marrow Transplant 31 (2003) 667-678
3. Bierman P.J., Sweetenham J.W., Loberiza Jr. F.R., et al. Syngeneic hematopoietic stem cell transplantation for non-Hodgkin's lymphoma: a comparison with allogeneic and autologous transplantation. The Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation. J Clin Oncol 21 (2003) 3744-3753
4. Weiden P.L., Flournoy N., Thomas E.D., et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic marrow grafts. N Engl J Med 300 (1979) 1068-1073
5. Kolb H.J., Mittermuller J., Clemm C., et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 15 (1990) 2462-2465
6. van Besien K., Loberiza Jr. F.R., Bajorunaite R., et al. Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. Blood 102 (2003) 3521-3529
7. Butcher B.W., and Collins Jr. R.H. The graft-versus-lymphoma effect: clinical review and future opportunities. Bone Marrow Transplant 36 (2005) 1-17
8. Peggs K.S., Mackinnon S., and Linch D.C. The role of allogeneic transplantation in non-Hodgkin's lymphoma. Br J Haematol 128 (2005) 153-168
9. Russell N.H., Byrne J.L., Faulkner R.D., et al. Donor lymphocyte infusions can result in sustained remissions in patients with residual or relapsed lymphoid malignancy after allogeneic haemopoietic stem cell transplantation. Bone Marrow Transplant 36 (2005) 437-441
10. Grigg A., and Ritchie D. Graft-versus-lymphoma effects: clinical review, policy proposals, and immunobiology. Biol Blood Marrow Transplant 10 (2004) 579-590
11. Gribben J.G., Zahrieh D., Stephans K., et al. Autologous and allogeneic stem cell transplantation for poor-risk chronic lymphocytic leukemia. Blood 106 (2005) 4389-4996
12. Morris E.C., Thomson K., Craddock C., et al. Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma. Blood 104 (2004) 3865-3871
13. Marks D.I., Lush R., Cavenagh J., et al. The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation. Blood 100 (2002) 3108-3114
14. Bethge W.A., Hegenbart U., Stuart M.J., et al. Adoptive immunotherapy with donor lymphocyte infusions after allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Blood 103 (2004) 790-795
15. Khouri I.F., Lee M.S., Saliba R.M., et al. Nonablative allogeneic stem cell transplantation for chronic lymphocytic leukemia: impact of rituximab on immunomodulation and survival. Exp Hematol 32 (2004) 28-35
16. Dreger P., Brand R., Hansz J., et al. Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using reduced-intensity conditioning. Leukemia 17 (2003) 841-848
17. Mandingers C.M., Verdonck L.F., Meijerink J.P., et al. Graft-versus-lymphoma effect of donor lymphocyte infusion in indolent lymphomas relapsed after allogeneic stem cell transplantation. Bone Marrow Transplant 32 (2003) 1159-1163
18. Ries L.A.G., Eisner M.P., Kosary C.L., et al. SEER Cancer Statistics Review 1975-2002 (2005), National Cancer Institute, Bethesda, MD
19. Mielcarek M., Martin P.J., Leisenring W., et al. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood 102 (2003) 756-762
20. Kottardis P.D., Milligan D.W., Chopra R., et al. In vivo CAMPATH-1 H prevents graft-versus-host disease after nonmyeloablative stem cell transplantation. Blood 96 (2000) 2419-2425
21. Chakraverty R., Peggs K.S., Chopra R., et al. Limiting transplantation-related mortality after unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen. Blood 99 (2002) 1071-1078
22. Mohty M., Bay J.O., Faucher C., et al. Graft-versus-host disease after allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen. Blood 102 (2003) 470-476
23. Pérez-Simón J.A., Kottardis P.D., Martino R., et al. Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders. Blood 100 (2002) 3121-3127
24. Chakrabarti S., Mackinnon S., Chopra R., et al. High incidence of cytomegalovirus infection after nomyeloablative stem cell transplantation: potential role of Campath-1 H in delaying immune reconstitution. Blood 99 (2002) 4357-4363
25. Peggs K.S., Thomson K., Hart D.P., et al. Dose-escalated donor lymphocyte infusions after reduced-intensity transplantation: toxicity, chimerism, and disease responses. Blood 103 (2004) 1548-1556
26. Storb R., Deeg H.J., Whitehead J., et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft-versus-host disease after marrow transplantation for leukemia. N Engl J Med 314 (1986) 729-735
27. Cheson B.D., Bennett J.M., Grever M., et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 87 (1996) 4990-4997
28. Cheson B.D., Horning S.J., Coiffier B., et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI-Sponsored International Working Group. J Clin Oncol 17 (1999) 1244-1253
29. Przepiorka D., Weisdorf D., Martin P., et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 15 (1995) 825-828
30. Hart D.P., Avivi I., Thomson K.J., et al. Use of 18F-FDG positron emission tomography after allogeneic transplantation to guide adoptive immunotherapy with donor lymphocyte infusions. Br J Haematol 128 (2005) 1065-1069
31. Maloney D.G., Grillo-Lopez A.J., White C.A., et al. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 90 (1997) 2188-2195
32. Maloney D.G., Grillo-Lopez A.J., Bodkin D.J., et al. IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol 15 (1997) 3166-3274
33. McLoughlin P., Grillo-Lopez A.J., Link B.K., et al. Rituximab chimeric anti-patients respond to a four-dose treatment program. J Clin Oncol 16 (1998) 2825-2833
34. Huss R., Deeg H.J., Gooley T., et al. Effect of MC on graft-versus-host disease, disease recurrence and survival after HLA-identical marrow transplantation for aplastic anemia or chronic myelogenous leukemia. Bone Marrow Transplant 18 (1996) 767-776
35. Walker H., Singer C.R., Patterson J., et al. The significance of host haemopoietic cells detected by cytogenetic analysis of bone marrow from recipients of bone marrow transplants. Br J Haematol 62 (1986) 385-391
36. Petz L.D., Yam P., Wallace R.B., et al. Mixed haematopoietic chimerism after bone marrow transplantation for hematologic malignancies. Blood 70 (1987) 1331-1337
37. Schattenberg A., De Witte T., Salden M., et al. Mixed hematopoietic chimerism after allogeneic transplantation with lymphocyte-depleted bone marrow is not associated with a higher incidence of relapse. Blood 73 (1989) 1367-1373
38. Pérez-Simón J.A., Caballero D., Diaz-Campello M., et al. Chimerism and minimal residual disease monitoring after reduced-intensity conditioning (RIC) allogeneic transplantation. Leukemia 16 (2002) 1423-1431
39. Baron F., Maris M.B., Sandmaier B.M., et al. Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. J Clin Oncol 23 (2005) 1993-2003
40. Thiede C., Florek M., Bornhäuser M., et al. Rapid quantification of MC using multiplex amplification of short-tandem repeat markers and fluorescence detection. Bone Marrow Transplant 23 (1999) 1055-1060
41. Mapara M.Y., Kim Y.-M., Wang S.-P., et al. Donor lymphocyte infusions mediate superior graft-versus-leukemia effects in mixed compared to fully allogeneic chimeras: a critical role for host antigen-presenting cells. Blood 100 (2002) 1903-1909
42. Baron F., Little M.T., and Storb R. Kinetics of engraftment after allogeneic hematopoietic cell transplantation with reduced-intensity or nonmyeloablative conditioning. Blood Rev 19 (2005) 153-164
43. Childs R., Clave E., Contentin N., et al. Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses. Blood 94 (1999) 3234-3241
44. Petersen S.L., Madsen H.O., Ryder L.P., et al. Chimerism studies in HLA-identical nonmyeloablative hematopoietic stem cell transplantation point to the donor CD8(+) T-cell count on day +14 as a predictor of acute graft-versus-host disease. Biol Blood Marrow Transplant 10 (2004) 337-346
45. Mattsson J., Uzunel M., Brune M., et al. Mixed chimaerism is common at the time of acute graft-versus-host disease and disease response in patients receiving non-myeloablative conditioning and allogeneic stem cell transplantation. Br J Haematol 115 (2001) 935-944